We are a growing Chinese pharmaceutical company developing therapeutics for patients in China and beyond.  
The first program is the IL-17A mAb licensed from Janssen. We have attracted experienced minds in drug reaserch and development.
Our team brings together scientists from China, the US and Europe. Our current focus is therapeutics for auto-immune disease and cancer.

05/19

2021

04/13

2021

12/21

2020

06/24

2020

04/12

2020

02/10

2020

NEWS & EVENTS
Better affordable medicines for patients in China and beyond.